Antisense Oligonucleotides for Reducing Tau mRNA and Protein Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tau-associated diseases are inadequate in effectively reducing tau mRNA and protein expression, leading to neurofibrillary tangle formation and associated pathologies.
Innovation Solution
Development of antisense oligonucleotides targeting human microtubule-associated protein tau (MAPT) with specific nucleobase sequences and 2'-modifications, which can decrease tau mRNA and protein expression through various mechanisms, including steric blocking and RNase H activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for tau-associated diseases, then disease management is maintained, but tau mRNA and protein expression is not effectively reduced, leading to neurofibrillary tangle formation
Solution Approach 1:
The patent extracts and removes harmful tau mRNA and protein expression through antisense oligonucleotides that specifically bind to and degrade tau mRNA, preventing protein synthesis. This directly addresses the harmful factor without affecting other cellular processes.
Solution Approach 2:
The patent introduces antisense oligonucleotides as intermediary molecules that mediate between the treatment administration and the target tau mRNA. These oligonucleotides serve as the active therapeutic agents that specifically interact with and reduce tau expression.
2Reliability
If antisense oligonucleotides with 2'-modifications are developed, then tau mRNA and protein expression is reduced, but treatment complexity increases
Solution Approach 1:
The patent applies 2'-modifications (such as 2'-O-methoxyethyl or 2'-fluoro) only to specific positions within the oligonucleotide sequence, particularly in regions critical for stability and binding affinity. This localized modification approach optimizes therapeutic effect while managing structural complexity.
Solution Approach 2:
The patent creates composite oligonucleotide structures combining modified nucleotides with standard nucleotides, and incorporating various chemical modifications (2'-modifications, backbone modifications, conjugates) to achieve enhanced stability and activity while maintaining manageable complexity through systematic design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antisense oligonucleotides achieve significant reduction of tau mRNA and protein levels, providing a therapeutic approach for tau-associated diseases by inhibiting their expression and potentially halting disease progression.
Implementation Method 1
antisense oligonucleotides targeting human microtubule-associated protein tau (MAPT) with specific nucleobase sequences
Implementation Method 2
decrease tau mRNA and protein expression through various mechanisms, including steric blocking and RNase H activation
Implementation Method 3
decrease tau mRNA and protein expression through various mechanisms, including steric blocking and RNase H activation
Data Source
Figure 1A
Figure 1B~1C
Figure 1D~1E
AI summary
Provided herein are compositions and methods for decreasing tau mRNA and protein expression. These compositions and methods are useful in treating tau-related diseases and disorders.